| David Mark Belcher, MD | |
|
191 Independence Ave, Quincy, MA 02169-7751 | |
| (617) 773-5070 | |
| (617) 472-2380 |
| Full Name | David Mark Belcher |
|---|---|
| Gender | Male |
| Speciality | Pediatrics |
| Location | 191 Independence Ave, Quincy, Massachusetts |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1578554713 | NPI | - | NPPES |
| 3122034 | Medicaid | MA | |
| 079152 | Other | MA | TUFTS HEALTH PLAN |
| 200759 | Other | MA | HPHC |
| J14528 | Other | MA | BLUE SHIELD OF MA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208000000X | Pediatrics | 79152 (Massachusetts) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| David Mark Belcher, MD 191 Independence Ave, Quincy, MA 02169-7751 Ph: (617) 773-5070 | David Mark Belcher, MD 191 Independence Ave, Quincy, MA 02169-7751 Ph: (617) 773-5070 |
News Archive
Details of a unique, ambitious and decades-long investigation into the causes of breast cancer - The Breakthrough Generations Study - were revealed today by Breakthrough Breast Cancer, the UK's leading breast cancer charity, and The Institute of Cancer Research, one of the world's leading cancer research organisations.
Gilead Sciences, Inc. has announced receipt of a Paragraph IV Certification Notice Letter advising that Teva Pharmaceuticals submitted an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration (FDA) requesting permission to manufacture and market a generic version of Atripla (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg). Atripla is currently sold in the United States through a joint venture between Bristol-Myers Squibb and Gilead.
A major study shows that a minimally-invasive procedure is as effective and safe as the gold standard for treating blockages of the carotid artery, giving patients who prefer a less invasive procedure a proven alternative.
Black women with stage I or II breast cancer are more likely than their counterparts of other races to abandon chemotherapy before completing their full course of treatment, according to a recent Columbia University Medical Center study.
› Verified 7 days ago
Dr. Lisa Brancato Corkins, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 500 Congress St, Suite 1f, Quincy, MA 02169 Phone: 617-471-3411 Fax: 617-471-3584 | |
Dr. George Hom, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 101 Adams Street, Suite 20, Quincy, MA 02169 Phone: 617-773-7754 Fax: 617-328-0957 | |
Mary Mcgaugh, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 191 Independence Ave, Quincy, MA 02169 Phone: 617-773-5070 Fax: 617-472-2380 | |
Beata Joanna Brzozowska, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 500 Congress St, Suite1f, Quincy, MA 02169 Phone: 617-471-3411 Fax: 617-471-3584 | |
Dr. Anne Ireys Lennon, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 54 Billings Road, Quincy, MA 02171 Phone: 617-773-5400 Fax: 617-773-5420 | |
Eric M Anderson, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 1250 Hancock St, Quincy, MA 02169 Phone: 617-774-0600 Fax: 617-774-0211 | |
Laura Scharf, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 191 Independence Ave, Quincy, MA 02169 Phone: 617-773-5070 Fax: 617-472-2380 |